Cargando…
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
INTRODUCTION: Various multigene predictors of breast cancer clinical outcome have been commercialized, but proved to be prognostic only for hormone receptor (HR) subsets overexpressing estrogen or progesterone receptors. Hormone receptor negative (HRneg) breast cancers, particularly those lacking HE...
Autores principales: | Yau, Christina, Esserman, Laura, Moore, Dan H, Waldman, Fred, Sninsky, John, Benz, Christopher C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096978/ https://www.ncbi.nlm.nih.gov/pubmed/20946665 http://dx.doi.org/10.1186/bcr2753 |
Ejemplares similares
-
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk
por: Yau, Christina, et al.
Publicado: (2013) -
Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
por: Ovcaricek, Tanja, et al.
Publicado: (2019) -
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
por: Shimelis, Hermela, et al.
Publicado: (2018) -
Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
por: Jacobson, Anne
Publicado: (2022) -
Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)